Nifty’s Pharma index saw a decline after US President Trump announced a 100 percent tariff on branded drugs from October 1. Analysts noted India’s limited exposure to patented drugs in the US market. Most Indian firms focus on generic medicines, which are not affected by the new tariff. Major Indian players also operate manufacturing facilities within the United States.
10 smallcap stocks surge up to 65% in 3 months despite market weakness
Over the past three months, the Nifty 50 has declined nearly 4%, while the Nifty Smallcap 350 index has shed around 2.5%, reflecting weakness across
October 17, 2026